PPA
LCTX icon

Parametric Portfolio Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Parametric Portfolio Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27,975
Closed -$69K – 3727
2021
Q4 		$69K Sell
27,975
-128
-0.5% -$300 ﹤0.01% 3586
2021
Q3 		$71K Buy
28,103
+4,874
+21% +$12.5K ﹤0.01% 3558
2021
Q2 		$66K Buy
23,229
+1,165
+5% +$3.01K ﹤0.01% 3519
2021
Q1 		$52K Buy
+22,064
New +$53K ﹤0.01% 4021
2019
Q1 		– Sell
-16,696
Closed -$15K – 3950
2018
Q4 		$15K Sell
16,696
-21,567
-56% -$33K ﹤0.01% 3890
2018
Q3 		$79K Sell
38,263
-4,481
-10% -$9.41K ﹤0.01% 3872
2018
Q2 		$77K Buy
42,744
+1,499
+4% +$3.02K ﹤0.01% 3826
2018
Q1 		$97K Buy
41,245
+25,106
+156% +$58.9K ﹤0.01% 3862
2017
Q4 		$30K Buy
16,139
+1,464
+10% +$3.2K ﹤0.01% 3886
2017
Q3 		$36K Buy
14,675
+1,102
+8% +$2.73K ﹤0.01% 4001
2017
Q2 		$37K Buy
+13,573
New +$37.9K ﹤0.01% 3973

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parametric Portfolio Associates's LCTX Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Lineage Cell Therapeutics (LCTX) in Q1 2022, closing a stake of 27,975 shares — an estimated $69K sold.

Parametric Portfolio Associates first reported a position in LCTX in Q2 2017 and held it in 11 quarters. The position peaked at $97K in Q1 2018. 110 funds tracked by Wall St. Rank hold LCTX as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Lineage Cell Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 27,975 Lineage Cell Therapeutics shares in Q1 2022, an estimated $69K.
  • Parametric Portfolio Associates first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 11 quarters.
  • Parametric Portfolio Associates's Lineage Cell Therapeutics position peaked at $97K in Q1 2018.
  • 110 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.